Blood Biomarker Kallikrein-8 Detects Amnestic Mild Cognitive Impairment
|
By LabMedica International staff writers Posted on 10 Jan 2022 |
|
Image: The Human KLK8/Kallikrein-8 ELISA Kit PicoKine is used to quantitate Human KLK8 in cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA) (Photo courtesy of Boster Biological Technology)
Alzheimer’s disease (AD) is a neurodegenerative disease and the most common cause of dementia. AD starts to damage the brain 20 years or more before any clinical symptoms appear. The currently available biomarker for AD (beta-amyloid (Aβ, A), tau (T), and neurodegeneration (N), (ATN)) are measured in cerebrospinal fluid (CSF).
The extracellular serine protease kallikrein-8 (KLK8, alias neuropsin) is a well-known, dose-dependent modulator of neuroplasticity and memory. It unfolds its effects in part by processing the substrates neuregulin-1, neuronal cell adhesion molecule L1, fibronectin, and ephrin receptor B2, and thereby regulates different neuroplasticity associated signaling pathways.
Neuropathologists at the University Hospital Essen (Essen, Germany) and their colleagues examined whether blood KLK8 is elevated in persons with amnestic mild cognitive impairment (aMCI) which is a precursor of AD, compared to cognitively unimpaired (CU) controls. Forty cases and 80 controls, matched by sex and age (± 3years), were participants of the longitudinal population-based Heinz Nixdorf Recall study. Standardized cognitive performance was assessed five (T1) and 10 years after baseline (T2).
KLK8 levels were measured in duplicate using a commercially obtained ELISA kit (Boster Biological Technology, Pleasanton, CA, USA). To discriminate between the APOE alleles ε2, ε3, and ε4, Cardio-MetaboChip BeadArrays were used for genotyping of two single-nucleotide polymorphisms (rs7412 and rs429358). Participants defined as APOE ε4 positive had at least one allele 4 (2/4, 3/4, 4/4). All other participants were defined as APOE ε4 negative.
The investigators reported that the 37 participants with aMCI had a higher KLK8 mean value compared to the 72 CU participants (911.6 ± 619.8 pg/mL versus 783.1 ± 633.0 pg/mL). Participants with aMCI were more often APOE ε4 positive compared to CU participants (48.6 versus 26.4%). Fully adjusted, a KLK8 increase of 500pg/mL was associated with a 2.68 (1.05–6.84) higher chance of having aMCI compared to being CU. With an AUC of 0.92 (0.86–0.97), blood KLK8 was a strong discriminator for aMCI and CU.
The authors concluded that the population-based case-control study demonstrated the capability of KLK8 as a blood biomarker for early diagnosis of AD. A 500 pg/mL increase in blood KLK8 was associated with an almost threefold increased chance of an aMCI diagnosis compared to cognitively unimpaired participants. The diagnostic performance of KLK8 in blood for aMCI was very good with an AUC of 0.92. The study was published on December 20, 2021 in the journal Alzheimer's Research & Therapy.
Related Links:
University Hospital Essen
Boster Biological Technology
The extracellular serine protease kallikrein-8 (KLK8, alias neuropsin) is a well-known, dose-dependent modulator of neuroplasticity and memory. It unfolds its effects in part by processing the substrates neuregulin-1, neuronal cell adhesion molecule L1, fibronectin, and ephrin receptor B2, and thereby regulates different neuroplasticity associated signaling pathways.
Neuropathologists at the University Hospital Essen (Essen, Germany) and their colleagues examined whether blood KLK8 is elevated in persons with amnestic mild cognitive impairment (aMCI) which is a precursor of AD, compared to cognitively unimpaired (CU) controls. Forty cases and 80 controls, matched by sex and age (± 3years), were participants of the longitudinal population-based Heinz Nixdorf Recall study. Standardized cognitive performance was assessed five (T1) and 10 years after baseline (T2).
KLK8 levels were measured in duplicate using a commercially obtained ELISA kit (Boster Biological Technology, Pleasanton, CA, USA). To discriminate between the APOE alleles ε2, ε3, and ε4, Cardio-MetaboChip BeadArrays were used for genotyping of two single-nucleotide polymorphisms (rs7412 and rs429358). Participants defined as APOE ε4 positive had at least one allele 4 (2/4, 3/4, 4/4). All other participants were defined as APOE ε4 negative.
The investigators reported that the 37 participants with aMCI had a higher KLK8 mean value compared to the 72 CU participants (911.6 ± 619.8 pg/mL versus 783.1 ± 633.0 pg/mL). Participants with aMCI were more often APOE ε4 positive compared to CU participants (48.6 versus 26.4%). Fully adjusted, a KLK8 increase of 500pg/mL was associated with a 2.68 (1.05–6.84) higher chance of having aMCI compared to being CU. With an AUC of 0.92 (0.86–0.97), blood KLK8 was a strong discriminator for aMCI and CU.
The authors concluded that the population-based case-control study demonstrated the capability of KLK8 as a blood biomarker for early diagnosis of AD. A 500 pg/mL increase in blood KLK8 was associated with an almost threefold increased chance of an aMCI diagnosis compared to cognitively unimpaired participants. The diagnostic performance of KLK8 in blood for aMCI was very good with an AUC of 0.92. The study was published on December 20, 2021 in the journal Alzheimer's Research & Therapy.
Related Links:
University Hospital Essen
Boster Biological Technology
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines
Channels
Molecular Diagnostics
view channel
Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
Two studies have identified proteins in the blood that could potentially alert individuals to the presence of cancer more than seven years before the disease is clinically diagnosed. Researchers found... Read more (1)_1.jpg "Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)"){kind=small}
Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations... Read more_1.jpg "Image: The innovative method to customize and strengthen DNA origami structure promises breakthroughs in medicine (Photo courtesy of Shutterstock)")
.jpg "Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)")
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E... Read more
HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV).... Read more
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
Technology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
